Literature DB >> 23163400

The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations.

Laure Elens, Dennis A Hesselink, Ron H N van Schaik, Teun van Gelder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23163400      PMCID： PMC3690115          DOI： 10.1111/bcp.12038

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

2.  Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

Authors:  B Ma; T Prueksaritanont; J H Lin
Journal:  Drug Metab Dispos       Date:  2000-02       Impact factor: 3.922

3.  Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.

Authors:  Laure Elens; Ron H van Schaik; Nadtha Panin; Martine de Meyer; Pierre Wallemacq; Dominique Lison; Michel Mourad; Vincent Haufroid
Journal:  Pharmacogenomics       Date:  2011-09-08       Impact factor: 2.533

4.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Authors:  Laure Elens; Rachida Bouamar; Dennis A Hesselink; Vincent Haufroid; Ilse P van der Heiden; Teun van Gelder; Ron H N van Schaik
Journal:  Clin Chem       Date:  2011-09-08       Impact factor: 8.327

5.  Validation of tacrolimus equation to predict troughs using genetic and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; David P Schladt; William S Oetting; Robert E Leduc; Ajay K Israni; Weihua Guan; Arthur J Matas; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

6.  Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.

Authors:  Teun van Gelder; Helio Tedesco Silva; Johan W de Fijter; Klemens Budde; Dirk Kuypers; Gunnar Tyden; Aleksander Lohmus; Claudia Sommerer; Anders Hartmann; Yann Le Meur; Michael Oellerich; David W Holt; Burkhard Tönshoff; Paul Keown; Scott Campbell; Richard D Mamelok
Journal:  Transplantation       Date:  2008-10-27       Impact factor: 4.939
  6 in total
  18 in total

1.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

2.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

Review 3.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Authors:  Rebecca A Pulk; David S Schladt; William S Oetting; Weihua Guan; Ajay K Israni; Arthur J Matas; Rory P Remmel; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2015-06-12       Impact factor: 2.533

Review 5.  Challenges in pharmacogenetics.

Authors:  Ingolf Cascorbi; Oliver Bruhn; Anneke N Werk
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 6.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

7.  Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Authors:  T Vanhove; P Annaert; D Lambrechts; D R J Kuypers
Journal:  Pharmacogenomics J       Date:  2016-07-05       Impact factor: 3.550

8.  Role of pharmacogenomics in dialysis and transplantation.

Authors:  Kelly Birdwell
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

9.  Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes.

Authors:  Jessica K Roberts; Chad D Moore; Robert M Ward; Garold S Yost; Christopher A Reilly
Journal:  J Pharmacol Exp Ther       Date:  2013-03-19       Impact factor: 4.030

Review 10.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.